Study of the outcome of patients with myeloma nephropathy on treatment with High Cut Off Haemodialysis (HCO-HD) in addition to chemotherapy at the Launceston General Hospital

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12612000024842

Acronym

HCO-HD

Enrollment

Registered

2012-01-06

Start date

2009-08-01

Completion date

2011-08-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Light chain myeloma commonly associated with renal failure. Therefore, it is important to preserve the renal function early by applying high cut off haemodialysis. It is worthwhile to asses the effectiveness of the combination of high cut off haemodialysis (HCO-HD) in addition of chemotherapy We are aiming to increase the awareness of this new treatment and also to document the results of the patients received this treatment in the last few years until end of next year.

Interventions

To assess the effectiveness of high cut off haemodialysis (HCOD) daily for 8 hours until the serum free light chain level become below 500 mg/L, in addition to chemotherapy in light chain myltiple myeloma disease patients who present at the Launceston General Hospital (LGH) and treated conjointly by the the Haematology and Renal teams. The observation time is 12 months per patient following tretment.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with multiple myeloma who have a light chain disease and renal impairment

Exclusion criteria

patients who have low light chain disease that not cause renal impairment

Outcome results